(1)
The amounts shown in this column are valued based on the aggregate grant date fair value computed in accordance with FASB ASC Topic 718 and, in the case of the performance shares, are based upon the probable outcome of the applicable performance conditions. See Note 19 to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, for a discussion of the relevant assumptions used in calculating the amounts.
(2)
The amounts in column (e) represent the actual amounts paid to Ms. Schertell and Mr. Rickheim under Neenah’s pre-Merger annual incentive program that was determined based on performance prior to the consummation of the Merger and with payout subject to the executive’s continued employment with the Company post-Merger. This amount is included in the Non-Equity Incentive Plan Compensation column in the 2022 Summary Compensation Table.
(3)
The amounts in columns (d), (e) and (f) consist of the threshold, target and maximum cash award levels for the post-Merger portion of 2022. The amount actually earned by each continuing Named Executive Officer is included in the Non-Equity Incentive Plan Compensation column in the 2022 Summary Compensation Table.
(4)
The amounts in columns (h) and (i) represent the target and maximum number of PSUs that may be earned based on the Company’s Synergy Run Rate Achievement during the period beginning on July 6, 2022 and ending December 31, 2024, subject to the Named Executive Officer’s continued employment through such date.
(5)
The amounts in columns (d), (e) and (f) consist of the threshold, target and maximum cash award levels for the pre-Merger portion of 2022 under SWM’s 2022 annual incentive program, pro-rated for the portion of 2022 that occurred prior to the closing of the Merger. The amount actually earned by each Named Executive Officer is included in the Non-Equity Incentive Plan Compensation column in the 2022 Summary Compensation Table.
(6)
The amounts in columns (h) and (i) represent the target and maximum number of performance shares that could have been earned based on the Company’s TSR as compared to the applicable peer group during the three-year performance period. In connection with the Merger, these awards were converted into time-based RSUs that will cliff vest on January 30, 2025, subject to the Named Executive Officer’s continued employment through such date.
(7)
The amounts in columns (g), (h) and (i) consist of the threshold, target and maximum performance shares that could have been earned during the 2022-2023 performance period based on the Company’s adjusted EBITDA performance, subject to a +/- 15% modifier based on the Company’s TSR performance, and were scheduled to vest on the first anniversary of the date on which the Committee certified the adjusted EBITDA and TSR achievement levels. In connection with the Merger, these awards were converted to time-based RSUs that vest 100% on February 16, 2025, subject to the Named Executive Officer’s continued employment through such date.
(8)
These amounts represent shares of service-based restricted stock which vested 50% on February 16, 2023 and the remaining 50% will vest on February 16, 2024, subject to continued employment through each applicable vesting date.
(9)
Represents the incremental fair value, calculated in accordance with FASB ASC Topic 718, arising from the modification on August 8, 2022 of the performance share awards granted in 2021 to Messrs. Wamser, Hoek and Nuñez that was made in connection with the Merger, pursuant to which the performance share awards were converted into RSU awards that will vest 100% on February 16, 2024. This amount does not represent a new equity grant.
(10)
Represents the incremental fair value, calculated in accordance with FASB ASC Topic 718, arising from the modification on August 11, 2022 of the performance share awards granted in 2022 to Messrs. Wamser, Hoek and Nuñez that was made in connection with the Merger, pursuant to which the performance share awards were converted into RSU awards that will vest 100% on February 16, 2025. This amount does not represent a new equity grant.
(11)
Represents the incremental fair value, calculated in accordance with FASB ASC Topic 718, arising from the modification on July 6, 2022 of the equity awards granted in 2021 to Dr. Kramer and Ms. Peacock that was made in connection with the Merger, pursuant to which they received settlement